Should all women get BRCA genetic testing as part of ‘routine medical care’? Key panel says ‘no’

| | February 22, 2019
2-20-2019 mammogram breast cancer x ray exlarge
Image credit: CNN
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Primary care providers should screen women for personal, family and/or ethnic history of breast, ovarian, tubal or peritoneal cancer to decide who should undergo genetic counseling for BRCA1 and BRCA2 mutations, the US Preventive Services Task Force recommended [February 19]. The mutations increase a woman’s cancer risk.

The draft guidance, which is open to a month of public comment, is likely to stir a simmering medical debate over how widely genetic testing should be used to screen women for the BRCA mutations.

Geneticist Mary-Claire King, who discovered the BRCA mutations and their link to breast cancer risk in 1990, said she’d like every woman to be offered complete sequencing of BRCA1 and BRCA2 as part of routine medical care.

Related article:  A right to know? Should children be told when a parent's genetic test reveals hereditary risks?

[Genetic testing] enables those women to take steps to reduce their risk, including undergoing enhanced or additional screening, chemoprevention and risk-reducing surgeries.

“All women, regardless of personal or family history of cancer, should be offered complete sequencing of BRCA1 and BRCA2 as part of routine medical care at about age 30 or at their current age if they are already older,” [King] said.

Read full, original post: New recommendations say not all women need genetic testing for cancer. Critics say it could cost lives

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend